Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2010
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Pooled it
- Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.Scientific reports · 2016Trial
- Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2016Trial
- Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.Clinical radiology · 2014Trial
- Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm.European radiology · 2014Trial
- Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals.European journal of radiology · 2013Trial
- Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours.Cancer imaging : the official publication of the International Cancer Imaging Society · 2012Trial
- Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Trial
- Comparing quantitative imaging biomarker alliance volumetric CT classifications with RECIST response categories.Radiology advances · 2025Article
- Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer:AJR. American journal of roentgenology · 2023Review
- Analysis of correlation of pre-therapeutic assessment and the final diagnosis in endometrial cancer: role of tumor volume in the magnetic resonance imaging.Frontiers in oncology · 2023Article
- Tumor Size Measurements for Predicting Hodgkin's and Non-Hodgkin's Lymphoma Response to Treatment.Metabolites · 2022Article
- Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity-modulated radiotherapy era.Cancer medicine · 2022Article
- CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1.Radiology. Imaging cancer · 2021Article
- Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions.Tomography (Ann Arbor, Mich.) · 2021Article
- Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.Journal of the National Cancer Institute · 2020Article
- Tumor volume is more reliable to predict nodal metastasis in non-small cell lung cancer of 3.0 cm or less in the greatest tumor diameter.World journal of surgical oncology · 2020Article
- Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer.Radiation oncology (London, England) · 2020Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
purposeTissue biomarker discovery is potentially limited by conventional tumor measurement techniques, which have an uncertain ability to accurately distinguish sensitive and resistant tumors. Semiautomated volumetric measurement of computed tomography imaging has the potential to more accurately capture tumor growth dynamics, allowing for more exact separation of sensitive and resistant tumors and a more accurate comparison of tissue characteristics. EXPERIMENTAL
designForty-eight patients with early stage non-small cell lung cancer and clinical characteristics of sensitivity to gefitinib were studied. High-resolution computed tomography was done at baseline and after 3 weeks of gefitinib. Tumors were then resected and molecularly profiled. Unidimensional and volumetric measurements were done using a semiautomated algorithm. Measurement changes were evaluated for their ability to differentiate tumors with and without sensitizing mutations.
resultsForty-four percent of tumors had epidermal growth factor receptor-sensitizing mutations. Receiver operating characteristic curve analysis showed that volumetric measurement had a higher area under the curve than unidimensional measurement for identifying tumors harboring sensitizing mutations (P = 0.009). Tumor volume decrease of >24.9% was the imaging criteria best able to classify tumors with and without sensitizing mutations (sensitivity, 90%; specificity, 89%).
conclusionsVolumetric tumor measurement was better than unidimensional tumor measurement at distinguishing tumors based on presence or absence of a sensitizing mutation. Use of volume-based response assessment for the development of tissue biomarkers could reduce contamination between sensitive and resistant tumor populations, improving our ability to identify meaningful predictors of sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.